Lozenge Extract Mixture Neutralizing SARS-CoV-2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for effective treatment methods against COVID-19, as no known method can treat the disease globally, despite the development of 19 different vaccines.
Innovation Solution
A mixture of green tea, bilberry, pomegranate peel, and black poplar Propolis extracts is formulated into lozenge/chewable tablets, which have been proven effective against SARS-CoV-2 virus in vitro, providing a protective effect around the mouth and throat.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If herbal extracts are used to treat COVID-19 through the digestive system, then the immune system is strengthened, but the active ingredients are metabolized extensively under varying pH and enzyme conditions, reducing effectiveness
Solution Approach 1:
The patent applies preliminary action by formulating extracts in lozenge/chewable tablet form that dissolves in the mouth before swallowing, allowing the active ingredients to act locally on the oral mucosa and throat first, where SARS-CoV-2 receptors are concentrated, before any metabolic degradation can occur in the digestive system
Solution Approach 2:
The patent applies local quality by targeting the delivery of herbal extracts specifically to the oral cavity and throat regions where SARS-CoV-2 enters the body, rather than systemic distribution through the digestive system. This localized delivery ensures the active ingredients remain concentrated at the point of viral entry
2Reliability
If lozenge/chewable tablets are used to deliver extracts locally in the mouth, then the protective effect around mouth and throat is enhanced, but the manufacturing complexity increases
Solution Approach 1:
The patent applies universality by using common lozenge/chewable tablet formulation techniques that are already well-established in the pharmaceutical and confectionery industries. The base ingredients (sucrose, glucose, starch, gelatin) and processing methods (molding, drying) are universal and widely used, minimizing the need for specialized manufacturing equipment or processes
3Reliability
If a combination of multiple herbal extracts is used against SARS-CoV-2, then the synergistic effectiveness is improved, but the quantity of substances and formulation complexity increases
Solution Approach 1:
The patent applies merging by combining multiple herbal extracts (green tea, bilberry, pomegranate peel, black poplar propolis) into a single integrated lozenge/chewable tablet formulation. This consolidation delivers all active ingredients simultaneously to the target site, achieving synergistic antiviral effects while maintaining a manageable product form
Data Source
AI summary
Clean version of Abstract A mixture consisting of extracts of green tea, bilberry, pomegranate peel, and black poplar Propolis is produced. Upon revealing the surprising efficacy of the mixture against SARS-CoV-2 virus, the mixture was put into lozenge/chewable tablet form and its activity against the SARS-CoV-2 virus was demonstrated. The invention was developed in the form of a throat lozenge/chewable tablet in order to provide a protective effect around the mouth and throat, which is the first point of entry of the SARS-CoV-2 virus. The effectiveness of the mixture against SARS-CoV-2 virus was tested on VERO E6 cells by in vitro methods. In the experiments lasting 160 hours, the mixture neutralizes the virus by 112% (61% cell viability) at 110 μg/mL concentration and by 35% (82% cell viability) at 70 μg/mL concentration. The combination of herbal extracts with Propolis extract were synergically more effective (−7-fold higher) than that of individual extract.